Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02310893 · ClinicalTrials.gov registry record · NA

Effectiveness of Peer Navigation and Contingency Management on Retention in HIV Care

A NA study of HIV/AIDS, sponsored by University of California, Los Angeles.

Completed
Registry status
NA
Development phase
579
Enrollment target
6
Study locations

NCT02310893: Completed NA study of HIV/AIDS, sponsored by University of California, Los Angeles.

NCT02310893 is a NA study of HIV/AIDS that has completed, run by University of California, Los Angeles. The registered enrollment target is 579 participants, below the 33,171-participant average among 61 other HIV/AIDS trials with a reported enrollment target (98% lower). The trial reports 6 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02310893, a NA study of HIV/AIDS, has completed, sponsored by University of California, Los Angeles.

COMPLETED
Registry status
NA
Development phase
579 participants
Enrollment target
6
Study locations

Study Summary

Consistent treatment with anti-retroviral therapy (ART) suppresses viral load (VL), prolonging life and improving quality of life for HIV+ persons. Suppressing VL benefits communities by reducing transmission to others. Mere availability of ART and care, however, is insufficient; the benefits of ART depend upon HIV+ persons' continuous visits to the health care provider, regular monitoring and regular delivery of medications, - known as retention in HIV care. In spite of national efforts, up to a quarter of HIV+ persons, especially low-income minorities are out of care. Innovative interventions are therefore urgently needed to maximize engagement and retention in HIV care, self-reported adherence, as well as HIV-1 RNA viral load suppression. In pursuit of these aims, the proposed study will assess outcomes of the following interventions in comparison to usual care: 1) contingency management (CM) only; 2) peer navigation (PN) only; and 3) a combined approach that integrates both CM and PN (CA) which the investigators hypothesize to be most effective in improving HIV clinical outcomes.

Primary Outcome

Using a 2x2 factorial design, to examine the effect of the three interventions -- peer navigation, contingency management, combined approach and usual care -- and evaluate how well they improve retention in HIV care

Conditions Studied

Interventions

  • BEHAVIORAL Contingency Management
  • BEHAVIORAL Peer Navigation
  • BEHAVIORAL Combined Contingency Management and Peer Navigation

Study Locations (6)

California

  • Center for Health Justice - Los Angeles
  • Los Angeles Sheriff's Department - Los Angeles
  • AltaMed Health Services Corporation - Los Angeles
  • Oasis Clinic - Los Angeles
  • Olive View Medical Center - Sylmar
  • Northeast Valley Health Corporation - Van Nuys

Trial Details

FieldValue
Enrollment Target 579 participants
Start Date 2016-01
Est. Completion 2020-01
Phase NA

What the finished NCT02310893 record still lists

NCT02310893 is an interventional study that assigns participants to a tested intervention. The registered 579 participants enrollment target is mid-sized for trials with a published cap, below the 33,171-participant average among 61 other HIV/AIDS trials with a reported enrollment target (98% lower).

The record links to 1 condition, with HIV/AIDS appearing as the primary indexed condition, and to 3 interventions - of which Contingency Management is the first listed.

NCT02310893 lists 6 locations in 1 state (California).

Frequently Asked Questions

What is clinical trial NCT02310893 about?

NCT02310893 is a clinical study titled "Effectiveness of Peer Navigation and Contingency Management on Retention in HIV Care". Consistent treatment with anti-retroviral therapy (ART) suppresses viral load (VL), prolonging life and improving quality of life for HIV+ persons. Suppressing VL benefits communities by reducing transmission to others. Mere availability of ART and care, however, is insufficient; the benefits of ART...

What is the current status of trial NCT02310893?

This trial is currently completed. It is a NA study. The enrollment target is 579 participants. The study started on 2016-01. Estimated completion is 2020-01.

What conditions does trial NCT02310893 study?

This clinical trial studies the following conditions: HIV/AIDS.

What interventions are being tested in trial NCT02310893?

The interventions under investigation include: Contingency Management (BEHAVIORAL), Peer Navigation (BEHAVIORAL), Combined Contingency Management and Peer Navigation (BEHAVIORAL).

Who is sponsoring clinical trial NCT02310893?

This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02310893 being conducted?

This trial has 6 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for HIV/AIDS

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02310893's enrollment target sits among peer trials

579 8th of 61 higher than 54 of 61 other HIV/AIDS trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other HIV/AIDS trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04575935 · 580 participants · Phase 3

    Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial

  • NCT05143177 · 580 participants · Phase 2

    A Study to Evaluate the Efficacy and Safety of DA-1229 (Evogliptin) in Patient's Calcific Aortic Valve Disease With Mild to Moderate Aortic Stenosis (EVOID-AS)

  • NCT05696353 · 580 participants · Phase 3

    Teen Driving Translation Study (NIH)

  • NCT06578104 · 580 participants

    PULSED AF Post-Approval Study

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02310893, the US trial registry maintained by the National Library of Medicine. NCT02310893 (mid enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.